You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias

    SBC: Path Biotech, LLC            Topic: NIA

    PROJECT SUMMARY/ABSTRACT In response to National Institute on Aging's (NIA) strategic plan and PAS-19-317, we propose novel therapeuticsto treat Alzheimer disease and related dementias (ADRDs). We have developed novel combinations of three natural product compounds, which modulate complementary pathways in multiple types of CNS cells (i.e., neurons, microglia) associated with AD pathology. These c ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Novel multi-sensing seat cover system for prevention of sitting-related pressure injuries in individuals with Alzheimer's disease or related dementias

    SBC: Adapt Design Works, LLC            Topic: NIA

    ABSTRACT The long-term objective of this project is to create a sensor-based monitoring technology for use by caregivers, clinicians, and individuals living with Alzheimer’s disease or Alzheimer’s disease related dementia (AD/ADRD) to mitigate the risk of pressure injuries related to prolonged sitting. Pressure injury prevalence is disproportionately high in the aging AD/ADRD population due to ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease

    SBC: Metselex, Incorporated            Topic: 105

    ABSTRACT This Phase STTR Phase II proposal aims to engineer and scale-up a synthetic metabolic pathway in a microbial host to produce UDCA and related compounds. Additionally, the UDCA produced from the engineered synthetic metabolic pathway will be used to synthesize derivatives for testing in our Alzheimer’s Disease cell and animal models. The proposed work has high intellectual merit for the ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells

    SBC: MARPAM PHARMA LLC            Topic: NIAID

    Project Summary MarPam Pharma aims to develop a one-time treatment for achieving durable remission of human immunodeficiency virus (HIV), after which patients will no longer need to take antiretroviral therapy. Our treatment is an autologous HIV-specific chimeric antigen receptor (CAR) immune cell therapy that employs the CXCR5 chemokine receptor as a homing device to direct either anti-HIV T cell ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Two-for-one Stroke Thrombectomy:A novel Dual DAC to enhance navigability, lumen size, aspiration efficiency, and persistent flow arrest in mechanical thrombectomy

    SBC: PIRAEUS MEDICAL, INC.            Topic: 105

    PROJECT SUMMARY/ABSTRACT The long-term goal of this proposal is to improve the care of patients suffering from Large Vessel Occlusion Acute Ischemic stroke. Currently, mechanical thrombectomy techniques can achieve revascularization in over 70% of cases, and physicians are rapidly adoption aspiration thrombectomy over stent-trievers. Aspiration maintains equivalent angiographic and clinical outcom ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a new aspiration catheter solution for the treatment of large and medium vessel occlusions

    SBC: ANEUVAS TECHNOLOGIES INC            Topic: 104

    Project Summary/Abstract Stroke is the leading cause of serious long-term disability and accounts for 4.6 million disabled people in the United States. Stroke-related costs total over $46 billion in the United States each year.1 Of the nearly 800,000 Americans who have a stroke per year, 87% experience ischemic stroke1, of which 49%-86% are attributed to either large vessel occlusions (LVO) or med ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Biomarkers for Brain Resetting as an Assistive Tool in the Treatment of Status Epilepticus

    SBC: Epifocus LLC            Topic: 104

    The proposed phase-I STTR research is an interdisciplinary effort to develop more effective clinical management of Status Epilepticus (SE) in collaboration with one of the leading neurological institutes in the world, the Barrow Neurological Institute in Phoenix, Arizona. SE is a life-threatening neurological emergency that can occur without warning and is characterized by recurrent seizures witho ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. GENOMICE (Game Exploring Nuances in Offspring to Master Interactions of Chromosome Expression)

    SBC: SMART INFORMATION FLOW TECHNOLOGIES LLC            Topic: NHGRI

    PROJECT SUMMARY Genomics has become an essential element of biomedical science, playing multiple roles in rapidly addressing the COVID-19 pandemic, understanding medical complications to develop more effective preventative care and treatments, and modeling diseases in laboratory specimens for study. Despite the increasing relevance of genomics to people's everyday lives, genomics literacy in the U ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Prodrugs of potent and selective protease inhibitors as tauopathy therapeutics

    SBC: MYRIEL, INC.            Topic: 105

    PROJECT ABSTRACT Myriel, Inc., is a pharmaceutical start-up company founded in 2022 to find cures for tauopathies, including Alzheimer’s disease and related dementias (ADRD), which impair cognition in 32% of US adults 65 years and older. The goal of this Phase 1 STTR application is to provide Myriel with a brain-penetrant analogue of our lead compound, GPHR ‘739, the first potent, selective, r ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD

    SBC: MYOGENICA INC.            Topic: NIAMS

    PROJECT SUMMARY Duchenne muscular dystrophy (DMD) is the most common type of muscular dystrophy, caused due to mutations in the dystrophin gene. DMD is characterized by progressive muscle wasting and overall loss of muscle function. DMD patients become wheel chair dependant by 12 years of age and the associated cardiorespiratory complications result in their early death around 20 years of age. Dys ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government